TG Therapeutics, Inc. Expected to Post FY2017 Earnings of ($1.77) Per Share (TGTX)
TG Therapeutics, Inc. (NASDAQ:TGTX) – Equities researchers at Jefferies Group raised their FY2017 EPS estimates for TG Therapeutics in a research note issued on Thursday. Jefferies Group analyst M. Andrews now forecasts that the biopharmaceutical company will post earnings of ($1.77) per share for the year, up from their prior estimate of ($1.84). Jefferies Group also issued estimates for TG Therapeutics’ Q4 2017 earnings at ($0.45) EPS, FY2018 earnings at ($1.75) EPS, FY2019 earnings at ($1.71) EPS and FY2020 earnings at ($0.88) EPS.
TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.48) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.43) by ($0.05). TG Therapeutics had a negative return on equity of 155.38% and a negative net margin of 73,217.77%. The firm had revenue of $0.04 million for the quarter, compared to analyst estimates of $0.04 million. TRADEMARK VIOLATION NOTICE: This piece was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this piece on another website, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The legal version of this piece can be accessed at https://www.dailypolitical.com/2017/11/12/tg-therapeutics-inc-expected-to-post-fy2017-earnings-of-1-77-per-share-tgtx.html.
A number of other analysts have also weighed in on the stock. BidaskClub upgraded shares of TG Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Sunday, July 16th. ValuEngine lowered shares of TG Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, October 16th. SunTrust Banks, Inc. restated a “buy” rating and issued a $28.00 target price on shares of TG Therapeutics in a research report on Tuesday, October 3rd. Finally, Zacks Investment Research lowered shares of TG Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, August 4th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and nine have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $25.11.
Shares of TG Therapeutics (NASDAQ:TGTX) opened at $8.45 on Monday. TG Therapeutics has a 52-week low of $4.10 and a 52-week high of $15.35.
Large investors have recently modified their holdings of the company. JPMorgan Chase & Co. lifted its holdings in shares of TG Therapeutics by 44.0% during the second quarter. JPMorgan Chase & Co. now owns 364,025 shares of the biopharmaceutical company’s stock worth $3,658,000 after purchasing an additional 111,155 shares during the period. Goldman Sachs Group Inc. lifted its holdings in shares of TG Therapeutics by 152.8% during the first quarter. Goldman Sachs Group Inc. now owns 43,020 shares of the biopharmaceutical company’s stock worth $501,000 after purchasing an additional 26,001 shares during the period. Dupont Capital Management Corp acquired a new position in shares of TG Therapeutics during the second quarter worth $258,000. Ameriprise Financial Inc. acquired a new position in shares of TG Therapeutics during the first quarter worth $1,291,000. Finally, Parametric Portfolio Associates LLC acquired a new position in shares of TG Therapeutics during the first quarter worth $928,000. Institutional investors own 49.94% of the company’s stock.
About TG Therapeutics
TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.
Receive News & Ratings for TG Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.